MA30558B1 - Antagonistes de recepteurs cgrp monocycliques substitues - Google Patents

Antagonistes de recepteurs cgrp monocycliques substitues

Info

Publication number
MA30558B1
MA30558B1 MA31438A MA31438A MA30558B1 MA 30558 B1 MA30558 B1 MA 30558B1 MA 31438 A MA31438 A MA 31438A MA 31438 A MA31438 A MA 31438A MA 30558 B1 MA30558 B1 MA 30558B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
cgrp receptor
substituted monocyclic
cgrp
compounds
Prior art date
Application number
MA31438A
Other languages
English (en)
Inventor
Michael R Wood
Ian M Bell
Steven N Gallicchio
Harold G Selnick
Craig A Stump
C Blair Zartman
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA30558B1 publication Critical patent/MA30558B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de formule I : (dans laquelle les variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG et Y sont comme est décrit ici) qui sont des antagonistes des récepteurs du CGRP et qui sont utiles dans le traitement ou la prévention de maladies dans lesquelles le CGRP est impliqué, telles que la migraine. L'invention concerne aussi des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et compositions dans la prévention ou le traitement de ces maladies dans lesquelles le CGRP est impliqué.
MA31438A 2006-05-09 2008-12-04 Antagonistes de recepteurs cgrp monocycliques substitues MA30558B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79907106P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
MA30558B1 true MA30558B1 (fr) 2009-07-01

Family

ID=38556368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31438A MA30558B1 (fr) 2006-05-09 2008-12-04 Antagonistes de recepteurs cgrp monocycliques substitues

Country Status (23)

Country Link
US (3) US7629338B2 (fr)
EP (2) EP2029575B1 (fr)
JP (2) JP4435288B2 (fr)
KR (1) KR20090018107A (fr)
CN (1) CN101443323A (fr)
AR (1) AR060872A1 (fr)
AU (1) AU2007284994B2 (fr)
BR (1) BRPI0711352A2 (fr)
CA (1) CA2650932C (fr)
CR (1) CR10415A (fr)
DO (1) DOP2007000093A (fr)
EA (1) EA200870521A1 (fr)
EC (1) ECSP088872A (fr)
GE (1) GEP20115140B (fr)
HN (1) HN2008001667A (fr)
IL (1) IL195110A0 (fr)
MA (1) MA30558B1 (fr)
MX (1) MX2008014353A (fr)
NO (1) NO20085110L (fr)
PE (1) PE20080253A1 (fr)
TW (1) TW200813008A (fr)
WO (2) WO2007133491A1 (fr)
ZA (1) ZA200809275B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512459A (ja) * 2004-09-09 2008-04-24 メルク エンド カムパニー インコーポレーテッド アリールスピロラクタムｃｇｒｐ受容体拮抗薬
US8003792B2 (en) * 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
WO2007133491A1 (fr) * 2006-05-09 2007-11-22 Merck & Co., Inc. Antagonistes de récepteurs cgrp monocycliques substitués
US7951795B2 (en) 2006-12-08 2011-05-31 Merck Sharp & Dohme Corp. Constrained spirocyclic compounds as CGRP receptor antagonists
JP2010521457A (ja) 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
US8372859B2 (en) 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
WO2008130524A1 (fr) 2007-04-16 2008-10-30 Merck & Co., Inc. Antagonistes des récepteurs du cgrp aryl hétérocycliques
CA2683745A1 (fr) 2007-04-16 2008-10-30 Merck & Co., Inc. Antagonistes des recepteurs cgrp heterocycliques d'anilide bicyclique
CA2689217C (fr) * 2007-06-05 2016-02-16 Merck & Co., Inc. Antagonistes des recepteurs cgrp a base de carboxamide heterocyclique
US8163752B2 (en) 2007-06-07 2012-04-24 Merck, Sharp & Dohme Corp. Tricyclic anilide heterocyclic CGRP receptor antagonists
EP2065381A1 (fr) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes du CGRP
NZ585347A (en) 2007-10-18 2011-09-30 Boehringer Ingelheim Int Cgrp antagonists
EP2225223B1 (fr) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Composés organiques
JP2011512410A (ja) * 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト
WO2009120652A2 (fr) * 2008-03-28 2009-10-01 Merck & Co., Inc. Antagonistes des récepteurs cgrp monocycliques
AU2009283085A1 (en) * 2008-08-20 2010-02-25 Merck Sharp & Dohme Corp. Non-amidic linkers with branched termini as CGRP receptor antagonists
EP2331101A4 (fr) * 2008-09-08 2012-08-29 Merck Sharp & Dohme Antagonistes du récepteur cgrp d'amide monocyclique
AU2009293471A1 (en) * 2008-09-18 2010-03-25 Merck Sharp & Dohme Corp. Bicyclic dihydroimidazolone CGRP receptor antagonists
JP2012504625A (ja) 2008-10-03 2012-02-23 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニスト
JP2012505217A (ja) * 2008-10-10 2012-03-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニスト
WO2010077752A1 (fr) 2008-12-17 2010-07-08 Merck Sharp & Dohme Corp. Dérivés d'imidazolinone en tant qu'antagonistes de récepteurs cgrp
US8765763B2 (en) 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
WO2011005731A2 (fr) 2009-07-08 2011-01-13 Merck Sharp & Dohme Corp. Procédé de production d'antagoniste du récepteur cgrp
US20120121508A1 (en) * 2009-07-27 2012-05-17 Merck Sharp & Dohme Corp. Radiolabeled cgrp antagonists
EP2569310A1 (fr) 2010-05-11 2013-03-20 Pfizer Inc Composés morpholiniques convenant comme antagonistes de récepteurs de minéralcorticoïdes
WO2011153359A1 (fr) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Inhibiteurs du transporteur 1 de la glycine, procédés de fabrication associés, et utilisations associées
TWI501968B (zh) 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2012087777A1 (fr) 2010-12-22 2012-06-28 Merck Sharp & Dohme Corp. Antagonistes des récepteurs du cgrp indanecarboxamides hétérocycliques condensés
CA2830348A1 (fr) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Antagonistes spirohydantoines des recepteurs cgrp de type carboxamide de piperidine
WO2012129013A1 (fr) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Pipéridinone carboxamide spirohydantoïne, antagonistes du récepteur cgrp
WO2013138418A2 (fr) 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Procédé de production d'antagonistes du récepteur cgrp
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
US9227972B2 (en) 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
EP2846799B1 (fr) 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Antagonistes de récepteur de cgrp à base de spirolactame
SG11201605178WA (en) * 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
WO2017001433A1 (fr) 2015-06-29 2017-01-05 Galderma Research & Development Composés d'antagoniste de récepteur cgrp pour le traitement topique de troubles cutanés
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
EP3366286A1 (fr) 2017-02-22 2018-08-29 Johannes Keller Composés destinés au traitement de septicémie
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3206184A1 (fr) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Traitement de la migraine
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2023026205A1 (fr) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Traitement préventif de la migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
US20250353860A1 (en) * 2022-04-29 2025-11-20 Brise Pharmaceuticals Co., Ltd. Piperidine carboxamide azaindane derivative, method for preparing same, and use thereof
WO2024134683A1 (fr) * 2022-12-21 2024-06-27 Msn Laboratories Private Limited, R&D Center Nouvelle méthode de préparation de composés intermédiaires utilisés dans le traitement de la migraine
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法
CN118930542A (zh) * 2024-07-25 2024-11-12 电子科技大学长三角研究院(衢州) 抗猴痘病毒和天花病毒的新型结构化合物及其组合应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JP2001294574A (ja) * 2000-04-11 2001-10-23 Suntory Ltd カルシトニン受容体作動物質
JP4673294B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
EP1606264B1 (fr) 2003-03-14 2012-05-02 Merck Sharp & Dohme Corp. Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique
AU2004222328B2 (en) 2003-03-14 2009-10-08 Merck Sharp & Dohme Corp. Aryl spirohydantoin CGRP receptor antagonists
EP1606286B1 (fr) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
WO2004091514A2 (fr) 2003-04-15 2004-10-28 Merck & Co., Inc. Antagonistes des recepteurs de cgrp
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7476665B2 (en) 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
EP1641781B1 (fr) 2003-06-26 2013-03-06 Merck Sharp & Dohme Corp. Antagonistes du récepteur CGRP de benzodiazépine
EP1646611A1 (fr) 2003-07-15 2006-04-19 Merck & Co., Inc. Antagonistes des recepteurs cgrp de l'hydroxypyridine
CN101124217A (zh) 2004-01-29 2008-02-13 默克公司 Cgrp受体拮抗剂
JP2008512460A (ja) * 2004-09-08 2008-04-24 メルク エンド カムパニー インコーポレーテッド 単環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
JP2008512459A (ja) 2004-09-09 2008-04-24 メルク エンド カムパニー インコーポレーテッド アリールスピロラクタムｃｇｒｐ受容体拮抗薬
CA2579717A1 (fr) 2004-09-09 2006-03-23 Merck & Co., Inc. Antagonistes des recepteurs cgrp sous forme de spirolactame d'anilide tricyclique
US8003792B2 (en) 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
AU2005285083B2 (en) 2004-09-13 2011-03-10 Merck Sharp & Dohme Corp. Tricyclic anilide spirohydantoin CGRP receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US7659264B2 (en) 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
EP1802637B1 (fr) 2004-10-13 2008-10-15 Merck & Co., Inc. Antagonistes aux récepteurs de cgrp
DE602005027870D1 (de) 2004-10-14 2011-06-16 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
EP1856100B1 (fr) 2005-01-18 2010-05-05 Merck Sharp & Dohme Corp. Antagonistes de recepteurs du peptide lie au gene de la calcitonine (cgrp)
EP1861399B1 (fr) 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Antagonistes du recepteur du cgrp
CA2615463A1 (fr) 2005-07-29 2007-02-08 Merck & Co., Inc. Antagonistes des recepteurs de cgrp de benzodiazepine heterocyclique
EP1954135B1 (fr) 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Antagonistes du récepteur cgrp spirolactame-aryle
EP1954268B1 (fr) 2005-11-18 2012-09-26 Merck Sharp & Dohme Corp. Antagonistes du récepteur cgrp spirolactame bicycliques
EP1951042B1 (fr) 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Antagonistes du récepteur cgrp spirolactame tricycliques
US7968540B2 (en) 2005-11-18 2011-06-28 Merck Sharp & Dohme Corp. Spirohydantoin tricyclic CGRP receptor antagonists
EP1963532A4 (fr) 2005-12-07 2010-07-21 Univ Utah Res Found Methylation de l'adn en tant que cible pour le diagnostic et le traitement de la leucemie lymphocytaire chronique (llc)
WO2007133491A1 (fr) 2006-05-09 2007-11-22 Merck & Co., Inc. Antagonistes de récepteurs cgrp monocycliques substitués
JP5511379B2 (ja) 2006-07-21 2014-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｇｒｐレセプターアンタゴニスト
JP2010521457A (ja) 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
US8372859B2 (en) 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
CA2683745A1 (fr) 2007-04-16 2008-10-30 Merck & Co., Inc. Antagonistes des recepteurs cgrp heterocycliques d'anilide bicyclique

Also Published As

Publication number Publication date
WO2007133491A1 (fr) 2007-11-22
JP2010013449A (ja) 2010-01-21
US20100056498A1 (en) 2010-03-04
US20070265225A1 (en) 2007-11-15
EP2029575A1 (fr) 2009-03-04
PE20080253A1 (es) 2008-04-05
AU2007284994A1 (en) 2008-02-21
US7629338B2 (en) 2009-12-08
NO20085110L (no) 2009-02-06
US7625901B2 (en) 2009-12-01
JP2009536645A (ja) 2009-10-15
EP2024358A1 (fr) 2009-02-18
TW200813008A (en) 2008-03-16
CA2650932C (fr) 2013-01-22
AR060872A1 (es) 2008-07-16
CA2650932A1 (fr) 2008-02-21
EA200870521A1 (ru) 2009-04-28
DOP2007000093A (es) 2008-01-15
AU2007284994B2 (en) 2010-04-22
KR20090018107A (ko) 2009-02-19
BRPI0711352A2 (pt) 2011-09-27
MX2008014353A (es) 2008-11-24
US20080318927A1 (en) 2008-12-25
WO2008020902A1 (fr) 2008-02-21
EP2029575B1 (fr) 2014-10-22
EP2024358B1 (fr) 2014-11-05
US7893079B2 (en) 2011-02-22
CN101443323A (zh) 2009-05-27
IL195110A0 (en) 2009-09-22
GEP20115140B (en) 2011-01-10
HN2008001667A (es) 2011-07-22
JP4435288B2 (ja) 2010-03-17
ZA200809275B (en) 2009-10-28
ECSP088872A (es) 2008-12-30
CR10415A (es) 2009-01-27

Similar Documents

Publication Publication Date Title
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
GEP20115140B (en) Substituted spirocyclic cgrp receptor antagonists
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
EP1606264A4 (fr) Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique
WO2006029153A3 (fr) Antagonistes de recepteurs cgrp d'anilide spirolactame monocyclique
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
EP1605936A4 (fr) Antagonistes du recepteur cgrp d'aryl spirohydantoine
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
NO20072435L (no) CGRP-reseptorantagonister
MA30999B1 (fr) Composés.
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ATE466860T1 (de) Cgrp-rezeptorantagonisten
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
WO2005000807A3 (fr) Antagonistes du recepteur cgrp de benzodiazepine
MA31683B1 (fr) Composes et procedes pour moduler fxr
EP1794133A4 (fr) Antagonistes des recepteurs cgrp d'aryle-spirolactame
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
EP1793827A4 (fr) Antagonistes des recepteurs cgrp sous forme de spirolactame d'anilide tricyclique
SI1716152T1 (sl) Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
ATE493412T1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
ATE529107T1 (de) Ligustilid-derivate zur behandlung von entzündungserkrankungen